Kyntra Bio: A New Era for FibroGen as It Rebrands and Shifts Focus
On January 7, 2026, FibroGen, Inc. (Nasdaq: FGEN) announced a significant rebranding initiative—transitioning to a new identity as Kyntra Bio. This strategic move signals the company’s commitment to pioneering therapies in oncology and rare diseases. The rebranding will be effective as of January 8, 2026, when Kyntra Bio will commence trading on Nasdaq under the new symbol “KYNB.”
Transitioning to Kyntra Bio
The rebranding reflects FibroGen’s journey and renewed direction, focusing on innovative treatments with the potential for substantial patient impact. CEO Thane Wettig emphasized the transformation, stating, “2025 was a transformational year, highlighted by the sale of FibroGen China, the payoff of our senior secured term loan, and the extension of our cash runway into 2028.”
Company’s Focus on Key Assets
With its rebranding, Kyntra Bio will concentrate on several critical assets, including:
- FG-3246: A first-in-class antibody-drug conjugate targeting CD46, currently in Phase 2 development for metastatic castration-resistant prostate cancer.
- FG-3180: A companion PET imaging agent in a Phase 2 trial that aims to assess correlation between CD46 expression and response to FG-3246.
- Roxadustat: This Phase 3 ready asset recently received Orphan Drug Designation for the treatment of myelodysplastic syndromes (MDS) from the FDA.
Milestones and Upcoming Developments
Kyntra Bio is preparing for several crucial presentations and trials in 2026:
- Topline results from the Phase 1b/2 study of FG-3246, in combination with enzalutamide for mCRPC, are anticipated to be presented at ASCO GU in the first quarter of 2026.
- Interim results from the FG-3180 Phase 2 trial are expected in the second half of 2026, which will also evaluate the agent's diagnostic performance.
- The pivotal Phase 3 clinical trial protocol for roxadustat targeting anemia in patients with lower-risk MDS is submitted for FDA consideration.
About Kyntra Bio
Kyntra Bio is a biopharmaceutical company dedicated to developing novel therapies that address significant medical needs in oncology and rare diseases. The firm’s lead product, Roxadustat (爱瑞卓®, EVRENZO™), is already approved in several countries, including Europe and Japan, for anemia in chronic kidney disease patients.
Conclusion and Investor Insights
The shift to Kyntra Bio denotes a pivotal phase that aligns with the company’s strategic objectives and product pipeline. As investors and stakeholders adapt to this change, Kyntra Bio aims to innovate and deliver on the expectations set forth during this transition. With a robust pipeline and a refreshed corporate strategy, Kyntra Bio is well-positioned for the future.
For more information, visit www.kyntrabio.com.